ABSTRACT
Immunological memory is a fundamental feature of the adaptive immune system. However emerging evidence
demonstrates that the innate immune system can also display a form of adaptive, memory-like behavior, a
phenomenon termed “trained immunity.” Recently using single cell ATAC-seq we demonstrated that
immunization of humans with the AS03-adjuvanted H5N1 pandemic influenza vaccine stimulates persistent
epigenomic imprints in blood myeloid cells, that results in a heightened resistance to infection with
heterologous viruses Zika and Dengue viruses, and reduced chromatin accessibility of loci targeted by
the AP-1 transcription factors leading to reduced capacity to produce pro-inflammatory cytokines. These
observations raise several key questions: 1) Do SARS-CoV-2 infection and vaccination stimulate functionally
distinct long-term epigenetic innate reprogramming? 2) Is epigenetic imprinting of innate immunity “tunable,” by
sequential infections or vaccinations? 3) What is the impact of SARS-CoV-2 vaccination or infection on
epigenetic imprinting of innate immunity in tissues? 4) What are the mechanisms of innate memory induced by
vaccination and their effects on protection against heterologous pathogens?
These questions will be addressed in the following specific aims:
Aim 1. Perform a longitudinal analysis of the evolution of the innate response following sequential
rounds of SARS-CoV-2 infection or vaccination. We will perform a longitudinal analysis of the single cell
transcriptional and epigenetic landscape of the innate immune system using banked PBMCs collected before,
during and after infection from a COVID-19 cohort of healthcare workers and followed longitudinally from the
beginning of the pandemic, through every infection and vaccination.
Aim 2. Define the transcriptional and epigenetic landscape and function of myeloid cells in tissues. Most
studies have only examined epigenetic imprinting of innate immunity in the blood, and the effects in tissues
remain unclear. In sub-aim 2a we will assess the transcriptional and epigenomic landscape of myeloid-lineage
cells in human mucosal and lymphoid tissues obtained from organ donors. In sub-aim 2b, we will use banked
samples from completed studies in nonhuman primates to assess the transcriptional and epigenomic landscape
of innate immune cells in various tissues and blood following SARS-CoV-2 infection or vaccination.
Aim 3: To assess the mechanisms of innate memory induced by vaccination and their effects on
protection against heterologous pathogens. In this aim we will use mice to explore the mechanisms
underlying innate memory to vaccination, and its functional consequences on protection against heterologous
infections.
Public Health Relevance Statement
We will use novel systems biological approaches to determine whether the evolutionarily ancient innate
immune system has “immunological memory,” long thought to be a unique feature of the adaptive immune
system. This will be explored in humans in the context of SARS-CoV-2 infection and vaccination.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
066469933
UEI
S352L5PJLMP8
Project Start Date
01-September-2003
Project End Date
31-July-2029
Budget Start Date
01-May-2024
Budget End Date
30-April-2025
Project Funding Information for 2024
Total Funding
$396,354
Direct Costs
$365,913
Indirect Costs
$30,441
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$396,354
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 2U19AI057266-21 8834
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2U19AI057266-21 8834
Patents
No Patents information available for 2U19AI057266-21 8834
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2U19AI057266-21 8834
Clinical Studies
No Clinical Studies information available for 2U19AI057266-21 8834
News and More
Related News Releases
No news release information available for 2U19AI057266-21 8834
History
No Historical information available for 2U19AI057266-21 8834
Similar Projects
No Similar Projects information available for 2U19AI057266-21 8834